INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

Impact · against what's priced in

The news is largely non-material for HCA, as its price already accounts for legal noise from securities investigations. For TYRA and OSIS, the initiation of fraud investigations creates a fresh legal overhang, with TYRA facing specific headwinds from Grade 3 adverse events in its SURF302 trial.

HCA+0.00

Already priced in

The price assumes

The legal and regulatory noise from ongoing securities fraud investigations, which the price treats as a contained event